Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Xenon Pharmaceuticals Inc
XENE | US
53.46
USD1.16
2.22%
XENE | US
About Xenon Pharmaceuticals Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
03/06/2026
Close
53.46
Open
52.30
High
53.84
Low
52.30
Xenon Pharmaceuticals Inc. a clinical-stage biopharmaceutical company engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496 a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101 a Kv7 potassium channel opener which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352 a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy and other indications including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby Canada.
View LessXENE | US
Risk
27.6
Sharpe
1.22
Luna's Score
54/100
Recommendation
Hold
Luna says (XENE | US)
What's Working
Strength based on increasing price with high volume
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Sharpe Ratio (> 1.2)
What's not Working
Price Below SMA10D
High 6-Month Volatility (>65%)
Midcap (2B - 10B USD)
High Market Beta (> 0.8)
Declining Revenue (< 0%)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
23.8%1 month
27.6%3 months
103.4%6 months
77.4%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
3.89
Debt to equity
0.01
Debt to assets
0.01
Ent. to EBITDA
-11.81
Ent. to rev.
10.87K
PEG
-0.06
Other Fundamentals
EBITDA
-233.68M
MarketCap
4.05B
MarketCap(USD)
4.05B
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-100.00
Ret. on equity
-26.71
Short ratio
10.62
Short perc.
4.39
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
3.59
Range1M
6.64
Range3M
22.88
Volumes: Market Activity
Rel. volume
1.42
Price X volume
90.84M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -11.81 | - | Cheaper |
| Ent. to Revenue | 10,874.60 | - | Expensive |
| PE Ratio | - | 41.03 | - |
| Price to Book | 3.89 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 103.40 | - | Riskier |
| Debt to Equity | 0.01 | -1.23 | Expensive |
| Debt to Assets | 0.01 | 0.25 | Cheaper |
| Market Cap | 4.05B | - | Par |
